In what is arguably the first buyout led by an Indian private equity firm in the international market, ICICI Venture — the private equity arm of ICICI Bank— has acquired majority control in US-based clinical research company Radiant Research
ICICI Venture, one of the most active private equity funds in India managing funds in excess of $2 billion, has multiple exposure in the life sciences business. Its investment portfolio includes Arch Pharmalabs, Malladi Drugs, Bharat Biotech, I-Ven Pharma, RFCL, Metropolis, Perlecan, Avesthagen, Biocon, Medicorp and Intas Pharma.
source: economic times
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment